Which antibiotic used for Gram-positive ocular infections inhibits cell wall synthesis by binding D-Ala-D-Ala termini?

Study for the NBEO Microbiology exam. Prepare with flashcards and multiple choice questions, each with hints and explanations. Get ready for your exam!

Multiple Choice

Which antibiotic used for Gram-positive ocular infections inhibits cell wall synthesis by binding D-Ala-D-Ala termini?

Explanation:
Vancomycin works by directly binding to the D-Ala-D-Ala termini of the peptidoglycan precursors in the bacterial cell wall. This blocks the enzymes responsible for cross-linking and elongation of the cell wall, effectively halting wall synthesis and causing death of the bacterium. This mechanism is particularly important for Gram-positive organisms like Staphylococcus and Streptococcus, which is why vancomycin is used for Gram-positive ocular infections. Gram-negative bacteria are less affected because their outer membrane prevents vancomycin from reaching its target. Other drugs listed either inhibit cell wall synthesis in a different way (beta-lactams) or inhibit protein synthesis and are not specifically acting on the D-Ala-D-Ala termini, so they don’t fit this mechanism.

Vancomycin works by directly binding to the D-Ala-D-Ala termini of the peptidoglycan precursors in the bacterial cell wall. This blocks the enzymes responsible for cross-linking and elongation of the cell wall, effectively halting wall synthesis and causing death of the bacterium. This mechanism is particularly important for Gram-positive organisms like Staphylococcus and Streptococcus, which is why vancomycin is used for Gram-positive ocular infections. Gram-negative bacteria are less affected because their outer membrane prevents vancomycin from reaching its target. Other drugs listed either inhibit cell wall synthesis in a different way (beta-lactams) or inhibit protein synthesis and are not specifically acting on the D-Ala-D-Ala termini, so they don’t fit this mechanism.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy